3 Sep, 11:36LatestUltragenyx has always been a low-quality company that for a long time carried a premium solely because of its RARE ticker, trading like a generalist ETF. x.com RARE
Hated Moats InvestorContrarian Quality-Stock Research, 25 Years in Markets, GOOGL Since 20113 SepRAREUltragenyx's biggest independent catalyst failed spectacularly, breaking the bullish case. Approval of its first drug had raised the odds for a second drug due September 29, but the third drug was the largest independent lever, and its September/October readout has now failed. x.com x.com Ask Alva0
